Long-Term Effects of Xuezhikang on Blood Pressure in Hypertensive Patients with Previous Myocardial Infarction: Data from the Chinese Coronary Secondary Prevention Study (CCSPS)
- 23 November 2010
- journal article
- research article
- Published by Taylor & Francis Ltd in Clinical and Experimental Hypertension
- Vol. 32 (8), 491-498
- https://doi.org/10.3109/10641961003686427
Abstract
Several previous trials from Western population studies have showed that statins may help reduce blood pressure (BP). However, randomized clinical data is limited. Xuezhikang, a partially extract of red yeast rice, contains a family of naturally occurring statins, and has a marked impact on lipids, but it is unknown whether Xuezhikang has any effect on BP during long-term follow-up in the Chinese population. This is a post-hoc subgroup analysis of a randomized, double-blinded, placebo-controlled, parallel group clinical trial, Chinese Coronary Secondary Prevention Study (CCSPS). A total of 2704 hypertensive patients with previous myocardial infarction (MI) were assigned either to placebo (n = 1341) or to Xuezhikang (n = 1363) daily for an average of 4.5 years. The primary outcome was the unadjusted changes in mean arterial pressure (MAP) from baseline to 6 months. We also assessed systolic blood pressure (SBP), diastolic blood pressure (DBP), and pulse pressure. Analysis of covariance was used to calculate the adjusted effects of treatment on changes in these outcomes at 6, 12, 24, and 48 months post-randomization, after controlling for potential confounders. This analysis included 2704/4870 (55.5%) hypertensive patients for whom BP was measured at baseline and at least one follow-up visit after randomization. Median duration of the follow-up was 4.5 years (54 months), and 25 patients (0.92%) were lost to the last follow-up because of adverse effects. The results showed that the unadjusted and adjusted changes in MAP, SBP, DBP, or pulse pressure from baseline were not significantly different for Xuezhikang or placebo recipients at 6, 12, 24, and 48 months after randomization. In this post-hoc subgroup analysis, we failed to demonstrate any significant reducing effects of Xuezhikang on BP in Chinese hypertensive patients with previous MI, suggesting that further prospective study on the effects of statins on BP would be needed, especially in high-risk patients.Keywords
This publication has 23 references indexed in Scilit:
- Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemiaClinica Chimica Acta; International Journal of Clinical Chemistry, 2006
- Effects of simvastatin within two weeks on anti-inflammatory cytokine interleukin 10 in patients with unstable anginaHeart, 2005
- Long-term effects of statins on arterial pressure and stiffness of hypertensivesJournal of Human Hypertension, 2004
- Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart StudyAmerican Heart Journal, 2004
- Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs.American Journal of Hypertension, 2004
- Lipid lowering: another method of reducing blood pressure?Journal of Human Hypertension, 2002
- Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertensionJournal of the American College of Cardiology, 2002
- Use of Statins and Blood Pressure Control in Treated Hypertensive Patients with HypercholesterolemiaJournal of Cardiovascular Pharmacology, 2000
- Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)The American Journal of Cardiology, 1999
- Smoking, Serum Lipids, Blood Pressure, and Sex Differences in Myocardial InfarctionCirculation, 1996